Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2022-08-10 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
向不特定对象发行可转换公司债券募集资金使用可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed feasibility analysis report for the use of funds raised through a convertible bond issuance by Yunnan Watson Biotechnology Co., Ltd. It includes comprehensive descriptions of the projects to be funded, investment amounts, project backgrounds, economic benefits, and regulatory approvals. The content focuses on capital raising and the planned use of proceeds, which aligns with updates on company fundraising activities and capital structure changes. There are no financial statements or quarterly/yearly financial results presented, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a simple announcement or a certification letter, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). The document is best classified as a Capital/Financing Update (CAP) because it details the capital raising and the intended use of the proceeds from the convertible bond issuance.
2022-08-10 Chinese
关于使用募集资金实施玉溪沃森两化融合建设项目的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the use of previously raised funds (募集资金) for a specific project, namely the 玉溪沃森两化融合建设项目. It includes background on the original fundraising, the decision-making process by the board and supervisory committee, independent directors' opinions, financial advisor opinions, and project details such as investment amount, timeline, and feasibility. The document is not a full financial report but rather an update on capital usage and project investment plans. It is not an earnings release, annual report, or audit report. The focus on the use of raised funds and the approval process aligns with a Capital/Financing Update. The document length (6775 characters) and content indicate it is not a brief announcement or a report publication notice but a substantive update on capital usage. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-08-10 Chinese
2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "云南沃森生物技术股份有限公司2022 年半年度报告全文" which translates to "Yunnan Walvax Biotechnology Co., Ltd. 2022 Semi-Annual Report Full Text." It explicitly states it is a half-year report for the period January 1, 2022 to June 30, 2022. The content includes detailed financial data, management discussion and analysis, company overview, business operations, product sales, production, R&D, and other substantive financial and operational information. The document length is 15,000 characters, indicating a full report rather than a brief announcement. The presence of financial statements, management analysis, and comprehensive business review confirms this is an Interim / Quarterly Report. Therefore, the appropriate classification is "IR" for Interim / Quarterly Report with high confidence. H1 2022
2022-08-10 Chinese
关于子公司向银行申请综合授信及流动资金贷款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Yunnan Watson Biotechnology Co., Ltd. regarding its subsidiary Yuxi Watson applying for comprehensive credit and working capital loans from several banks. It includes details about the loan amounts, purposes, board and supervisory opinions, and financial indicators of the subsidiary. The document is a formal announcement of financing activity related to loans and credit facilities, not a full financial report or earnings release. It does not contain comprehensive financial statements or detailed financial analysis but focuses on the financing update and approval process. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2599 characters, which is consistent with an announcement rather than a full report.
2022-08-10 Chinese
关于向不特定对象发行可转换公司债券摊薄即期回报与公司拟采取的填补措施及相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement by Yunnan Watson Biotechnology Co., Ltd. regarding the issuance of convertible bonds to unspecified investors. It includes an analysis of the dilution impact on immediate returns, assumptions for financial projections, risk warnings, necessity and rationality of the issuance, relationship of the investment projects to existing business, measures to compensate for dilution, and commitments by the board and senior management to fulfill these measures. The document references regulatory approvals needed from the Shenzhen Stock Exchange and the China Securities Regulatory Commission. It is not a full financial report but a comprehensive capital/financing update about a convertible bond issuance, including financial impact analysis and corporate commitments. It does not contain full financial statements or quarterly/annual financial results but focuses on financing activity and related disclosures. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (7981 characters) and content confirm it is not a mere announcement of a report (RPA) or a regulatory filing (RNS).
2022-08-10 Chinese
关于无需编制前次募集资金使用情况报告的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company regarding the exemption from preparing a previous fundraising usage report. It references regulatory requirements from the China Securities Regulatory Commission about fundraising reports but states that no fundraising occurred in the last five years, so no report or audit is needed. The document is brief (571 characters) and serves as a regulatory compliance announcement rather than a full financial report or detailed filing. It does not contain financial statements or detailed data, nor is it a report itself. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-08-10 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.